Date: Monday, 04/17/2023
Time: 10:30 AM (view in the schedule)
Room: Centennial I, and virtual
Prior to the presentation, lunch will be served from 11:15-11:30 AM Eastern. The program should begin right at 11:30 AM Eastern; however, small delays are possible due to the meal. We thank you in advance for your patience.
Schizophrenia is a mental disorder characterized by disruptions in thought processes, perceptions, emotional responsiveness, and social interactions and requires continuous and effective long-term management to reduce symptoms, improve quality of life, and prevent relapses. While oral antipsychotics have proven to be efficacious for many patients, ongoing symptoms and relapse remain a problem due to nonadherence. Long-acting injectable (LAI) antipsychotics are an underutilized treatment alternative that, when administered early on, improve adherence and reduce/prevent relapses and hospitalizations. It is important that pharmacists are familiar with the substantial health and economic burdens associated with schizophrenia, including high rates of medication nonadherence and symptomatic relapses, to effectively identify patients who may be ideal candidates for LAI antipsychotics as well as counsel patients/caregivers about schizophrenia and possible treatments. This activity will discuss current guidelines and data on LAIs to enable pharmacists to make appropriate recommendations in the treatment of patients with schizophrenia.
HOW TO RECEIVE CREDIT
Please follow the instructions below to claim your credit:
NOTE: Participation data will not be uploaded into CPE monitor if you do not have your NABP (e-profile ID) number and date of birth entered in your profile.
All participants must request credit by June 17, 2023.
Lisa W. Goldstone, PharmD, MS, BCPS, BCPPView biographical information and disclosures